Nanomerics - Pharmaceutical Nanotechnology

“Nanomerics uses leading know-how in pharmaceutical nanotechnology to overcome the limitations of current medicines and develop products that deliver patient benefit in areas of unmet medical need.”

Nanomerics CEO Andreas Schatzlein presents at APS PharmSci Conference

Nanomercis has been selected to present at the SME Showcase Session at the annual APS PharmSci Conference 2014. The conference subtitled 'The Science of Medicines', held from the 8th – 10th September 2014 at the University of Hertfordshire De Havilland Campus, is the largest UK event for pharmaceutical scientists. Prof Schatzlein will give a brief update on the development of Nanomerics lead product NM0127, a novel therapy for the treatment of severe chronic pain to replace current morphine like opioids.  


Prof Martin Koltzenburg Joins Nanomerics Advisory Board

Nanomerics is pleased to announce the strengthening of its Scientific Advisory Board with the appointment of Professor Martin Koltzenburg.  Professor Koltzenburg’s appointment will  support the clinical development of iNanomerics' lead product NM0127, a novel pain therapeutic based on an endogenous peptide.  

Antibodies to the Brain - A High Impact Collaboration

Nanomerics is embarking on a new EPSRC funded collaborative research project with the Danish pharmaceutical company H Lundbeck, UCL, and Exeter University.  

LogosAs part of the new collaboration, the company aims to develop new and exciting ways to deliver antibodies to the brain, building on the molecular envelope technology Nanomerics has developed to deliver previously undeliverable drugs to the organ.

UCL’s School of Life and Medical Sciences Celebrates Enterprise Successes

UCL Enterprise publicationSpin-out Nanomerics and its founders were highlighted in UCL’s School of Life and Medical Sciences recently launched  'Enterprise' publication. The brochure, available here, celebrates recent success stories of translation of scientific knowledge. 

Dr Alan Bye joins Nanomerics' Board of Directors.

logoNanomerics is pleased to announce the appointment of Dr Alan Bye to Nanomerics' Board of Directors.  Alan Bye is an experienced and accomplished pharmaceutical scientist who previously ran GSK's Centre of Excellence in Neuroscience.  Dr Bye has taken numerous products from concept to market and brings valuable industrial and product development experience to the board.

Nanomerics new patent granted in Japan

 Nanomerics is pleased to announce that a Notice of Allowance has been received on one of its key MET patents - Japanese Patent  JP5469458. Nanomerics' CEO, Dr Andreas Schatzlein says, "we are delighted with this notice of allowance from the Japanese Patent Office.  This further strengthen's our MET patent estate and enables us to work  in a major and lucrative market".

Nanomerics Scientists Publish New Textbook on Pharmaceutical Nanotechnology

A new textbook on the fundamentals of pharmaceutical nanotechnology edited by Prof IF Uchegbu and Dr AG Schatzlein and colleagues has now been published  by Springer.  Prof Uchegbu, CSO of  Nanomerics said: 'The textbook focuses on design and application of a variety of nanosystems with utility in in the field of drug delivery.

Nanomerics CSO becomes International Controlled Release Society (CRS) Fellow

CRS logoAt the 2013 Controlled Release Society Nanomerics CSO was nominated to the CRS College of Fellows.  The College of Fellows recognizes CRS members who have made outstanding contributions to the field of delivery science and technology over a minimum of 10 years.  Only 5 fellowships are awarded annually. 

MET Fibrous Hydrogel
MET Fibrous Hydrogel
Subscribe to Nanomerics RSS